TY - JOUR
T1 - Multi-Cellular Immunological Interactions Associated With COVID-19 Infections
AU - Verma, Jitender S.
AU - Libertin, Claudia R.
AU - Gupta, Yash
AU - Khanna, Geetika
AU - Kumar, Rohit
AU - Arora, Balvinder S.
AU - Krishna, Loveneesh
AU - Fasina, Folorunso O.
AU - Hittner, James B.
AU - Antoniades, Athos
AU - van Regenmortel, Marc H.V.
AU - Durvasula, Ravi
AU - Kempaiah, Prakasha
AU - Rivas, Ariel L.
N1 - Funding Information:
The support facilitated by the Department of Medicine of Mayo Clinic Florida (SARDOM #93960006) is appreciated. The participation of Dr. F.O. Fasina was funded by the Food and Agriculture Organization of the United Nations through USAID Grant number GHA-G-00-06-00001, Support FAO Preparedness and Response Activities to Address the Novel Global Coronavirus (COVID-19) Outbreak in Tanzania.
Publisher Copyright:
Copyright © 2022 Verma, Libertin, Gupta, Khanna, Kumar, Arora, Krishna, Fasina, Hittner, Antoniades, van Regenmortel, Durvasula, Kempaiah and Rivas.
PY - 2022/2/24
Y1 - 2022/2/24
N2 - To rapidly prognosticate and generate hypotheses on pathogenesis, leukocyte multi-cellularity was evaluated in SARS-CoV-2 infected patients treated in India or the United States (152 individuals, 384 temporal observations). Within hospital (<90-day) death or discharge were retrospectively predicted based on the admission complete blood cell counts (CBC). Two methods were applied: (i) a “reductionist” one, which analyzes each cell type separately, and (ii) a “non-reductionist” method, which estimates multi-cellularity. The second approach uses a proprietary software package that detects distinct data patterns generated by complex and hypothetical indicators and reveals each data pattern’s immunological content and associated outcome(s). In the Indian population, the analysis of isolated cell types did not separate survivors from non-survivors. In contrast, multi-cellular data patterns differentiated six groups of patients, including, in two groups, 95.5% of all survivors. Some data structures revealed one data point-wide line of observations, which informed at a personalized level and identified 97.8% of all non-survivors. Discovery was also fostered: some non-survivors were characterized by low monocyte/lymphocyte ratio levels. When both populations were analyzed with the non-reductionist method, they displayed results that suggested survivors and non-survivors differed immunologically as early as hospitalization day 1.
AB - To rapidly prognosticate and generate hypotheses on pathogenesis, leukocyte multi-cellularity was evaluated in SARS-CoV-2 infected patients treated in India or the United States (152 individuals, 384 temporal observations). Within hospital (<90-day) death or discharge were retrospectively predicted based on the admission complete blood cell counts (CBC). Two methods were applied: (i) a “reductionist” one, which analyzes each cell type separately, and (ii) a “non-reductionist” method, which estimates multi-cellularity. The second approach uses a proprietary software package that detects distinct data patterns generated by complex and hypothetical indicators and reveals each data pattern’s immunological content and associated outcome(s). In the Indian population, the analysis of isolated cell types did not separate survivors from non-survivors. In contrast, multi-cellular data patterns differentiated six groups of patients, including, in two groups, 95.5% of all survivors. Some data structures revealed one data point-wide line of observations, which informed at a personalized level and identified 97.8% of all non-survivors. Discovery was also fostered: some non-survivors were characterized by low monocyte/lymphocyte ratio levels. When both populations were analyzed with the non-reductionist method, they displayed results that suggested survivors and non-survivors differed immunologically as early as hospitalization day 1.
KW - COVID-19
KW - biological complexity
KW - cutoff-free
KW - error prevention
KW - multi-cellularity
KW - pattern recognition
KW - personalized medicine
KW - personalized methods
UR - http://www.scopus.com/inward/record.url?scp=85126417356&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126417356&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2022.794006
DO - 10.3389/fimmu.2022.794006
M3 - Article
C2 - 35281033
AN - SCOPUS:85126417356
SN - 1664-3224
VL - 13
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 794006
ER -